QS-21 is a globally recognized and highly effective vaccine adjuvant. It is a core component of blockbuster vaccines such as GSK's shingles vaccine Shingrix, malaria vaccines, and mRNA vaccines, potently activating both cellular and humoral immunity. Traditional extraction relies on 30–50 year old Chilean soapbark trees (Quillaja saponaria), which are extremely scarce and command very high prices.

Longzang Biotech has introduced high‑quality germplasm and established a stable cultivation system for soapbark tree stem cells. Using 500L bioreactors, we have achieved large‑scale production, reducing the cost to just 5% of that of traditional processes, with a batch‑to‑batch coefficient of variation (CV) ≤2%. The result is a stable supply with consistent quality. This represents a key technological breakthrough that breaks the international monopoly and enables the domestic production of high‑end vaccine adjuvants in China.

-

QS-21 是全球公认的高效疫苗佐剂，为 GSK 带状疱疹疫苗 Shingrix、疟疾疫苗、mRNA 疫苗等重磅产品的核心成分，可强效激活细胞免疫与体液免疫。传统提取依赖 30–50 年生智利皂皮树，资源极度稀缺、单价极高。龙藏生物通过引进优质种源，构建皂皮树干细胞稳定培养体系，以 500L 生物反应器实现规模化生产，将成本降至传统工艺的 5%，批次差异 CV≤2%，供应稳定、质量可控，是打破国际垄断、实现高端疫苗佐剂国产化的关键技术突破。